iBio, Inc.’s Post

Conceptualization and execution with strategic planning develop an idea into a startup.

Commit Biologics welcomes Mikkel Wandahl Pedersen, as its new Chief Scientific Officer🚀   With over two decades of experience in #antibody-based drug discovery and development, Mikkel further strengthens our leadership team as we continue to advance our Bispecific Complement Engaging (#BiCE™) technology, designed to revolutionise treatments for #cancer and #autoimmune disease. 💊   Mikkel joins us from Nykode Therapeutics where, as CSO, he successfully created and executed a new research strategy, scaled the research organisation to support an expanding pipeline, and spearheaded key collaborations with external pharmaceutical partners.   He brings to Commit a wealth of knowledge in #immunooncology and #autoimmune research   To learn more about Mikkel's background see the press release, linked in the comments below 👇.   #CSO #Leadership #ComplementSystem

Thoughts on this? >> Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharma #healthcare #pharmaceutical

Thoughts on this? >> Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #productmarketing #biotech #pharmaceutical

Thoughts on this? >> Lexeo brings in $95M; FDA lifts hold on Nurix cancer trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharma #productmarketing #pharmaceutical

At Blueprint Medicines, we have successfully brought forward important, fundamental new medicines for patients since our founding 13 years ago. I am honored to join in discussions at the Biotechnology Innovation Organization (BIO) CEO & Investor Conference about strategies for maintaining an innovation-enabling environment, which may allow companies like Blueprint to deliver more transformational medicines in future. Please join me at our panel discussion today about overcoming challenges in oncology drug discovery and development.

Sanofi pays $110M upfront for late-stage radioligand therapy, setting up rivalry with Novartis. Sanofi has made a late entry to the radioligand party, paying 100 million euros ($110 million) upfront for global rights to a neuroendocrine tumor treatment that is nearing a filing for approval. The French drugmaker has stayed on the sidelines as a who’s who of drugmakers, led by Novartis, have placed big bets on radioligand therapies. Sanofi is entering the sector through a deal with Radiomedix, Inc. and Orano Med for a targeted alpha... Check out the full story 👉 https://zurl.co/iia1 (Fierce Biotech) #biotech #genetics

Recent advancements in #Cell and #gene therapies, #RNA therapeutics, and complex biologics offer unprecedented opportunities to treat complex diseases. However, traditional early discovery research spaces and large-scale manufacturing models are outdated. This necessitates new, integrated offerings like the ones we have at SmartLabs which combine reconfigurable lab infrastructure, operations, and scientific expertise to meet the modern demands of science. Our CEO @BrianTaylor recently spoke with BioPharma Dive on the ways in which these offerings are benefitting companies from small start-ups to established organizations as well as his vision for how to future-proof in an ever-changing industry. Read the full Q&A on BioPharma Dive: https://hubs.ly/Q02zkNX10 #Biopharma #HemophiliaB #DrugDevelopment #ClinicalTrials #DrugManufacturing #ClinicalData #BusinessDevelopment #Biopharma #DrugDiscovery #IND #FDA

The ImmunoBio Series 2024 - UK Edition is just around the corner, and we're proud to introduce our sponsor partners: Volition | Predicine | Ultivue | Proteome Sciences plc | GemPharmatech | EpigenDx, Inc. | ANGLE | Veracyte, Inc. | Canopy Biosciences | Ground Truth Labs | ViroCell Biologics | ICON plc | Akoya Biosciences, Inc. | Randox | Agilent Technologies | Charles River Laboratories | Rules-Based Medicine a Q² Solutions Company | Novogene Europe | Sino Biological, Inc. | Antibody Analytics of this insightful event. Happening on 07th-08th March at Park Plaza Victoria London, the series features two co-located conferences – the 5th Annual Biomarker and Companion Diagnostics Conference and the 8th Annual Next Gen Immuno-Oncology Conference. Join us in expressing gratitude to our sponsors for their unwavering commitment to advancing research and driving progress in these critical areas. Know more: https://lnkd.in/dngS_Gg6 #biomarker #personalizedmedicine #biomarkervalidation #companiondiagnostics #healthcare #pharma #healthcaretechnology #marketsandmarkets #ConferenceRegistration #oncology #oncologyresearch #cancer #medicine #oncologia #immunooncology #pharmaceutical

BIOSECURE Act is sidestped for now, where it is going the next ? how is global biotech doing to prepare? hear insights from Sarah Karlin-Smith from #BIO conference and #ASCO2024 highlights from Jie (Dexter) Yan #uschina #biotech #security #supplychain #oncology #adc #antibody